AIDS and cancer in the era of highly active antiretroviral therapy (HAART).
Combination therapy with protease inhibitors and nucleoside analogues dramatically suppresses plasma HIV-1 RNA and delays progression to AIDS, but the impact on HIV-associated malignancy remains to be established. Observational and time-trend data indicate that the incidence of Kaposi's sarcoma (KS) and primary brain lymphoma have decreased, but suggest that current therapies have not had a proportionate effect on systemic non-Hodgkin's lymphomas (NHL). As opportunistic infection and mortality are yielding to advances in antiretroviral therapy, lymphoma may increase in importance as a cause of AIDS-related morbidity and mortality. Further improvements in the long-term consequences of HIV infection will depend on better prevention and treatment of this serious malignant complication.
Rabkin
C S
CS
Viral Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892, USA. rabkinc@mail.nih.gov
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000188:drug therapy